Protagonist Therapeutics (NASDAQ: PTGX) turns Q2 2026 loss into profit
Protagonist Therapeutics (NASDAQ: PTGX) reported a significant financial turnaround in Q2 2026, shifting from a loss to a net income of $162.8 million and diluted earnings per share of $2.29. This was primarily driven by approximately $213.5 million in license and collaboration revenue, including …